Comparative immunogenicity of two vaccination schedules of a combined hepatitis A and B vaccine in healthy volunteers

Journal of Viral Hepatitis

Volumn 18, Issue 4, 2011, Pages

  De Schryver, Antoon ^a,b   Verstrepen, K ^a   Vandersmissen, L ^a   Vandermeeren, N ^a   Vernaillen, I ^a   Vranckx, R ^c   Van Damme, M ^b   Van Sprundel, ^b  

^a EXTERNAL SERVICE FOR PREVENTION AND PROTECTION AT WORK   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

HBV HAV combined vaccine; Occupational health; Vaccine schedules

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS ANTIBODY;

ADULT; ARTICLE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SWELLING; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADULT; ANIMALS; BELGIUM; FEMALE; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMAN EXPERIMENTATION; HUMANS; IMMUNIZATION SCHEDULE; MALE; MIDDLE AGED; VACCINES, COMBINED;

EID: 79952648576     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01365.x     Document Type: Article

References (24)

1. Morris-Cunnington MC, Edmunds WJ, Miller E, Brown DW. A population-based seroprevalence study of hepatitis A virus using oral fluid in England and Wales. Am J Epidemiol 2004; 159: 786-794. (Pubitemid 38656136)
2. Joussemet M, Depaquit J, Nicaud E et al. Fall in the seroprevalence of hepatitis A in French youth. Gastroenterol Clin Biol 1999; 23: 447-455.
3. Beutels P, Van Damme P, Vranckx R, Meheus A. The shift in prevalence of hepatitis A immunity in Flanders, Belgium. Acta Gastroenterol Belg 1998; 61: 4-7. (Pubitemid 28218131)
4. Termorshuizen F, Dorigo-Zetsma JW, De Melker HE, van den Hof S, Conyn-Van Spaendonck MA. The prevalence of antibodies to hepatitis A virus and its determinants in The Netherlands: a population-based survey. Epidemiol Infect 2000; 124: 459-466. (Pubitemid 30623863)
5. Vranckx P, Jacques P, Moens G. Prevalence of hepatitis A antibodies in a large sample of Belgian health care workers. Infection 1999; 27: 256-258. (Pubitemid 29443681)
6. Lahaye DL, Strauss P, Baleux C, Van Ganse W. Cost-benefit analysis of hepatitis-B vaccination. Lancet 1987; ii: 441-442.
7. Vranckx R, Jacques P, De Schrijver A, Moens G. Hepatitis B vaccination coverage in Belgian health care workers. Infection 2004; 32: 278-281. (Pubitemid 39319144)
8. Thoelen S, Van Damme P, Leentvaar-Kuypers A et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine 1999; 17: 1657-1662. (Pubitemid 29138897)
9. Van Damme P, Leroux-Roels G, Law B et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 2001; 65: 6-13.
10. Kane M. Reduced doses of hepatitis B vaccines: is it a good idea? Bull World Health Organ 1995; 73: 529-530.
11. Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 2007; 5: 79-84. (Pubitemid 46211211)
12. European European Consensus group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561-565.
13. Gunson RN, Shouval D, Roggendorf M et al. Hepatitis b virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCW's): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 2003; 27: 213-230. (Pubitemid 36870896)
14. Burgess MA, Rodger AJ, Waite SA, Collard F. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study. Vaccine 2001; 19: 4835-4841. (Pubitemid 32800770)
15. Rieger MA, Hofmann F, Michaelis M. Simultaneous vaccination against hepatitis A and B: results of an open, randomized study from the occupational health point of view. Int J Occup Med Environ Health 2004; 17: 379-391. (Pubitemid 39452226)
16. Rendi-Wagner P, Kundi M, Stemberger H et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001; 19: 2055-2060. (Pubitemid 32178355)
17. Stoffel M, Lievens M, Dieussaet I, Martin I, AndrÈ F. Immunogenicity of Twinrix in older adults: a critical analysis. Expert Rev Vaccines 2003; 2: 9-14. (Pubitemid 36564802)
18. Van der Wielen M, Van Damme P, Chlibek R, Smetana J, von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine 2006; 24: 5509-5515. (Pubitemid 43831382)
19. Joines RW, Blatter M, Abraham B et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrixand Engerix-B) in adults. Vaccine 2001; 19: 4710-4719. (Pubitemid 32800755)
20. Ambrosch F, Wiedermann G, AndrÈ F et al. Clinical and immunological investigation of a new combined hepatitis A and B vaccine. J Med Virol 1994; 44: 452-456.
21. Halsey NA, Moulton LH, O'Donovan JC et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics 1999; 103: 1243-1247. (Pubitemid 29258800)
22. Hadler SC, de Monzon MA, Lugo DR, Perez M. Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians. Vaccine 1989; 7: 106-110. (Pubitemid 19089664)
23. Jilg W, Schmidt M, Deinhardt F. Vaccination against Hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989; 160: 766-769. (Pubitemid 19266830)
24. Marsano LS, West DJ, Chan I et al. A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. Vaccine 1998; 16: 624-629. (Pubitemid 28112560)